Trimetozine (Opalene, Trimolide, Trioxazine) is a sedative that has been marketed in Europe since 1959.[1][2] It also has mild tranquilizing effects and has been used in the treatment of anxiety.[3][4] Its mechanism of action is unclear.[citation needed]
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.010.215 |
| Chemical and physical data | |
| Formula | C14H19NO5 |
| Molar mass | 281.308 g·mol−1 |
| 3D model (JSmol) | |
| |
Conversion of the amide in trimetozine to the thioamide gives Tritiozine.
References
edit- ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 1932. ISBN 3-88763-075-0.
- ^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0-412-46630-9.
- ^ Taverna P, Ferrari G (June 1970). "[Clinical trial of a new tranquilizing agent: trioxazine]". Minerva Medica (in Italian). 61 (46): 2574–90. PMID 5425739.
- ^ Shpak VM, Shcheglova AI (August 1968). "[Trioxazine in the treatment of night anxiety in children]". Pediatriia (in Russian). 47 (8): 76–7. PMID 5730033.